ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo

Event · Earnings
Original reporting
Published Nov 16, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ORIC
Bullish
medium confidence
Mentioned
$ORIC
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ORICBullishMed
01

Why it matters

This 8-K is a combined financial and pipeline execution update: it reiterates differentiated safety from a Periodic Safety Review, provides landmark rPFS durability snapshots in two post-treatment mCRPC cohorts, and initiates the Himalayas-1 global Phase 3 registrational trial with a stated enrollment plan and primary endpoint.

02

Market read

For traders, the actionable element is the new Phase 3 registrational initiation plus updated safety and durability readouts, which can re-rate probability-weighted outcomes ahead of future primary endpoint data.

03

What to watch

Cash runway is extended to 2H 2028, but the next major valuation inflection is the primary endpoint readout from the first Phase 3 trial, which remains a future binary risk.

Relevance 8/10Novelty 7/10Timing: after-hours filing on Nov 16, 2026
AlphAI · Earnings readORIC · Q3 2026 · ended 2026-09-30

ORIC reports Q3 2026 net loss of $(48,076) thousand as R&D expenses rise to $43.4 million

→Mixed quarter

The filing reports clinical and regulatory progress, including the start of the Himalayas-1 Phase 3 trial and the planned Redwood-1 trial, but the company reports no revenue, the net loss and operating expenses increased year over year, and total assets and equity declined from December 31, 2025.

EPS · GAAP
$(0.44)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, three months ended September 30, 2026GAAP$43.4M–increase of $14.6 million
General and administrative expenses, three months ended September 30, 2026GAAP$8.2M–increase of $0.3 million
Total operating expenses, three months ended September 30, 2026GAAP$51.55M––
Loss from operations, three months ended September 30, 2026GAAP−$51.55M––
Other income, net, three months ended September 30, 2026GAAP$3.48M––
Net loss, three months ended September 30, 2026GAAP−$48.08M––
Net loss per share, basic and diluted, three months ended September 30, 2026GAAP$(0.44)––
Comprehensive loss, three months ended September 30, 2026GAAP−$48.75M––
Research and development expenses, nine months ended September 30, 2026GAAP$111.1M–increase of $27.1 million
General and administrative expenses, nine months ended September 30, 2026GAAP$25.4M–increase of $0.9 million
Total operating expenses, nine months ended September 30, 2026GAAP$136.5M––
Loss from operations, nine months ended September 30, 2026GAAP−$136.5M––
Other income, net, nine months ended September 30, 2026GAAP$11.13M––
Net loss, nine months ended September 30, 2026GAAP−$125.3M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$(1.17)––
Comprehensive loss, nine months ended September 30, 2026GAAP−$127.8M––
Cash, cash equivalents and investments as of September 30, 2026other$345.4M––
Total assets as of September 30, 2026GAAP$366.9M––
Total stockholders' equity as of September 30, 2026GAAP$339.5M––

Capital returns

  • The filing reports $59.9 million in net proceeds raised from healthcare specialist funds during the first quarter under the at-the-market (ATM) program; this amount is included in the $345.4 million of cash, cash equivalents and investments as of September 30, 2026.
  • No share repurchases or dividends are reported in the filing.

What drove it

  • The company attributes the R&D increase for the three months ended September 30, 2026 primarily to higher external expenses related to the advancement of rinzimetostat, partly offset by lower enozertinib costs due to the timing of manufacturing and clinical costs.
  • The company attributes the nine-month R&D increase to higher external expenses related to rinzimetostat, partly offset by lower enozertinib costs due to the timing of manufacturing and clinical costs, and lower preclinical costs.
  • The company attributes the G&A increases for both periods primarily to higher professional services costs.
  • The company initiated the Himalayas-1 global Phase 3 trial in post-abiraterone mCRPC, supported by a clinical trial collaboration and supply agreement with Bayer, under which Bayer provides darolutamide at no cost for the trial.
  • The company announced the Redwood-1 global Phase 3 trial in 1L EGFR atypical NSCLC, with initiation expected in 1H 2027.
  • The company entered an agreement with Cancer Research UK under which CRUK will fully fund, sponsor and execute CTA-enabling activities and early clinical development of ORIC-259; ORIC retains an option to reacquire rights following Phase 1/2 data.

Concerns

  • The filing reports no revenue line; the company's results consist of operating expenses, other income and net loss.
  • Net loss increased to $(48,076) thousand for the three months ended September 30, 2026 from $(32,587) thousand a year earlier, and to $(125,335) thousand for the nine months from $(98,963) thousand.
  • Total operating expenses rose to $51,551 thousand from $36,671 thousand for the quarter.
  • Total assets fell to $366,886 thousand from $408,890 thousand at December 31, 2025, and stockholders' equity fell to $339,503 thousand from $384,362 thousand over the same period.
  • The company's cash, cash equivalents and investments of $345.4 million include $59.9 million from ATM proceeds raised in the first quarter.
  • The safety and efficacy data are described by the company as preliminary, with 28% of patients ongoing in the post-abiraterone cohort and 32% in the post-AR inhibitor cohort.
  • The enozertinib data presented at ESMO Congress 2026 are described as Phase 1b data, and median PFS and duration of response were immature as of the data cutoff.

What to watch

  • The anticipated primary endpoint readout from the first Phase 3 trial for rinzimetostat; the filing does not give a timing for this readout.
  • The 2H 2026 rinzimetostat program update.
  • Initiation of the Redwood-1 Phase 3 trial in 1H 2027.
  • Mid-2027 enozertinib data for the 1L EGFR exon 20 monotherapy and the combinations with SC amivantamab and chemotherapy.
  • Whether R&D expense continues to rise as the Himalayas-1 trial enrolls, which the company plans for approximately 600 patients across over 250 sites in 25 countries.
  • Whether the cash runway into 2H 2028 holds, given the reported decline in cash and investments and the need for additional funding that the company's risk factors describe.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were $261,376 thousand as of September 30, 2026, compared with $281,488 thousand as of December 31, 2025.
  • Long-term investments were $83,986 thousand as of September 30, 2026, compared with $110,762 thousand as of December 31, 2025.
  • Total assets were $366,886 thousand as of September 30, 2026, compared with $408,890 thousand as of December 31, 2025.
  • Total liabilities were $27,383 thousand as of September 30, 2026, compared with $24,528 thousand as of December 31, 2025.
  • Total stockholders' equity was $339,503 thousand as of September 30, 2026, compared with $384,362 thousand as of December 31, 2025.
  • The company expects its cash and investments to fund the operating plan into 2H 2028.
  • The filing does not include a cash flow statement, so operating cash flow and free cash flow are not reported.

Analysis

ORIC reported a net loss of $(48,076) thousand for the three months ended September 30, 2026, against $(32,587) thousand a year earlier, and a net loss of $(125,335) thousand for the nine months against $(98,963) thousand. The filing reports no revenue line, so the results reflect operating expenses and other income only. Total operating expenses for the quarter were $51,551 thousand against $36,671 thousand, with R&D at $43.4 million against $28.8 million and G&A at $8.2 million against $7.9 million. Other income, net was $3,475 thousand against $4,084 thousand for the quarter.

The company's own explanation for the R&D increase is higher external expenses related to the advancement of rinzimetostat, partly offset by lower enozertinib costs tied to the timing of manufacturing and clinical costs. The nine-month R&D figure of $111.1 million against $84.0 million carries the same explanation, with lower preclinical costs also cited. G&A increases are attributed by the company to higher professional services costs. The spending mix therefore points toward the rinzimetostat Phase 3 program, which the company says has begun with Himalayas-1, while enozertinib spending is lower in the period.

On capital, cash, cash equivalents and investments were $345.4 million at September 30, 2026, including $59.9 million of net ATM proceeds raised in the first quarter. The balance sheet shows total assets of $366,886 thousand and stockholders' equity of $339,503 thousand, compared with $408,890 thousand and $384,362 thousand at December 31, 2025. The company expects this cash to fund its operating plan into 2H 2028. The filing contains no cash flow statement, so operating cash burn for the period is not reported.

Clinical updates are the main content of the release. The company reported rinzimetostat safety data from a pre-planned Periodic Safety Review and landmark rPFS estimates in both mCRPC cohorts, which it describes as preliminary. It also presented enozertinib Phase 1b data at ESMO Congress 2026 with an 84% systemic ORR and a 70% CNS ORR by investigator, and announced the Redwood-1 Phase 3 trial with initiation expected in 1H 2027. The filing gives no financial guidance, so no guided figures can be compared with actual results.

The figures that deserve attention are the widening net loss, the rise in operating expenses in both periods, and the decline in total assets and equity since year-end. The clinical programs are described in the release in detail, but the filing does not provide the revenue, gross margin, cash flow or guidance figures that would allow a full financial comparison.

Management, verbatim

Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC

Jacob M. Chacko, M.D., president and chief executive officer

With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer

Jacob M. Chacko, M.D., president and chief executive officer

Not in the filing

stated, not guessed
  • No revenue or collaboration revenue line is reported in the filing.
  • No cost of sales or gross margin is reported.
  • No prior-quarter (June 30, 2026) figures are printed for any results line.
  • Percentage changes for total operating expenses, loss from operations, net loss, other income and EPS are not printed.
  • The prior-year figure for cash, cash equivalents and investments at September 30, 2025 is not printed.
  • The December 31, 2025 balance sheet figures are not year-over-year comparatives, so the prior_year fields for total assets and stockholders' equity are null.
  • No cash flow statement is included, so operating cash flow, investing cash flow, financing cash flow and free cash flow are not reported.
  • No debt or borrowing figures are reported.
  • No financial guidance or outlook figures are reported.
  • No non-GAAP measures or reconciliations are reported.
  • No timing is given for the anticipated primary endpoint readout from the first rinzimetostat Phase 3 trial.
  • Revenue by segment or product line is not reported, and the filing does not identify separate reportable segments.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

ORIC is a clinical-stage oncology company advancing rinzimetostat (PRC2 inhibitor) and enozertinib (EGFR atypical NSCLC) through late-stage development.

Company-level read

Ticker impact

$ORICBullishMedium confidence
Context

ORIC reports Q3 2026 financial results and updates rinzimetostat Phase 1b safety/durability plus initiates Himalayas-1 Phase 3 in 1H 2027.

Expected impact

Likely upward bias as investors price improved late-stage execution and differentiated safety/efficacy signals, offset by ongoing trial-risk.

Evidence & confidence

The 8-K includes new operational milestones (Phase 3 initiation, PSR results) and cash runway guidance, which can shift biotech valuation expectations even without an approval event.

Market effects

Reinforces competitive positioning among PRC2 inhibitor programs in prostate cancer, potentially affecting relative sentiment across the class.

Limited direct regional spillover beyond US biotech sentiment.

Global Phase 3 footprint (25 countries) may modestly influence international oncology trial-risk perception.

Counterpoint

Durability and rPFS are still described as preliminary with limited ongoing patient counts, so the data may not yet de-risk the primary Phase 3 endpoint.

Key entities

  • ORIC Pharmaceuticals, Inc.

    Subject of the 8-K, reporting Q3 2026 results and rinzimetostat operational updates including Phase 3 initiation and PSR findings.

  • rinzimetostat

    Allosteric PRC2 inhibitor in Phase 1b and Phase 3 Himalayas-1 trial in mCRPC.

  • Himalayas-1

    Global Phase 3 registrational trial in 1H 2027 expected initiation, enrolling ~600 patients across 25 countries.

  • Bayer

    Collaboration and supply agreement partner providing darolutamide (NUBEQA) at no cost for Himalayas-1.

  • enozertinib

    EGFR atypical NSCLC program with presented ESMO 2026 response metrics.

Every ORIC earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.